Discussion about this post

User's avatar
Hugo Navarro's avatar

Hello everyone, first of all thanks for your time to research all of this, as a shareholder of Intellego since it was at 25, and still buying shares, along with many subscribers who have positions in the company after reading my research, I think I am in a good position to address these claims.

First of all I think you abuse of estimations which lead you to low accurate conclusions as they pile up in top of each other. Intellego is a very different company now than it was a couple years ago so extrapolating past problems to the current moment when the management has improved with deloite accounting and a new CFO I think lead to false conclusions.

You are repeating the same bear arguments that shorts have been telling for the past few years all have been addresed and the company no longer suffers from this problems.

Part 1:

This one is easy to explain, YUVIO was a great development for the company to distribute their dosimeters, now they have major deals with distributors relying less on the devices, additionally you mention that these devices might be difficult to sell or make a profit on them, neither of those is the aim of Intellego they intend to sell dosimeters and the devices are sold at 0 margin and even accounted as capital expenditure as they are expected to generate profits from dosimeters not the sale.

In the order size quite easy to show an announcement 6 months ago in Linkedin: https://www.linkedin.com/feed/update/urn:li:activity:7304803511618162691/

Part 2:

You are talking about an order that is minimal, it would make complete sense to not mention it as it has grown insignificant compared to the new orders. Maybe you are correct on this one, however I do not think it presents a bear argument for the company in the present.

Part 3:

You are speculating to a completely new level, even if those were the producers in 2021 this could have changed as the company has grown, your conclusions that the sales are not being represented in the growth of these companies is completely non-sense. Are you trying to say that the company’s revenues are overstated despite being audited by Deloitte? This argument does not hold up neither. I know some investors who have visited the manufacturing and no red flags.

Part 4:

Another speculation with no basis. Nothing wrong with this point.

Part 5:

Cannot debunk this one yet, thanks for researching this one, however not very material at the current valuation. Let’s see how the partnership develops.

Part 6:

Non-sense, base case is 360 million, worth up to 1.4 billion if they extend the solution to all Asia.

Part 7:

Henkel will use and sell the dosimeters, as stated they are even negotiating a global distribution agreement. So the based assumptions are inherently wrong.

Part 8:

“Although we would admit that North America’s contribution in Q2 was unusually high, Intellego has historically seen large geographic fluctuations. The company has explained that reported regional splits have limited informational value, as orders from customers such as Likang or Henkel may be booked in different regions depending on order specifics.”

Part 9:

https://www.eqs-news.com/news/research/original-research-intellego-technologies-ab-von-montega-ag-buy/ff0bc265-b96f-40f2-81bf-229dea817f62_en

Jul's avatar

Regarding Henkel, it has been confirmed even by Sven Nordenstam (the bear journalist) https://x.com/SvenNordenstam/status/1895034170847699445

2 more comments...

No posts

Ready for more?